- Home
- NCL vs PHIO Comparison
NCL vs PHIO Comparison
Compare NCL & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCL
- PHIO
- Stock Information
- Founded
- NCL 2013
- PHIO 2011
- Country
- NCL United States
- PHIO United States
- Employees
- NCL N/A
- PHIO N/A
- Industry
- NCL
- PHIO Biotechnology: Pharmaceutical Preparations
- Sector
- NCL
- PHIO Health Care
- Exchange
- NCL Nasdaq
- PHIO Nasdaq
- Market Cap
- NCL 13.1M
- PHIO 12.1M
- IPO Year
- NCL 2023
- PHIO N/A
- Fundamental
- Price
- NCL $0.42
- PHIO $1.30
- Analyst Decision
- NCL
- PHIO Strong Buy
- Analyst Count
- NCL 0
- PHIO 3
- Target Price
- NCL N/A
- PHIO $10.67
- AVG Volume (30 Days)
- NCL 109.5K
- PHIO 8.7M
- Earning Date
- NCL 11-19-2025
- PHIO 11-13-2025
- Dividend Yield
- NCL N/A
- PHIO N/A
- EPS Growth
- NCL N/A
- PHIO N/A
- EPS
- NCL N/A
- PHIO N/A
- Revenue
- NCL $12,997,205.00
- PHIO N/A
- Revenue This Year
- NCL N/A
- PHIO N/A
- Revenue Next Year
- NCL N/A
- PHIO N/A
- P/E Ratio
- NCL N/A
- PHIO N/A
- Revenue Growth
- NCL N/A
- PHIO N/A
- 52 Week Low
- NCL $0.41
- PHIO $0.97
- 52 Week High
- NCL $12.16
- PHIO $9.79
- Technical
- Relative Strength Index (RSI)
- NCL 42.68
- PHIO 24.72
- Support Level
- NCL $0.41
- PHIO $1.50
- Resistance Level
- NCL $0.50
- PHIO $4.19
- Average True Range (ATR)
- NCL 0.04
- PHIO 0.31
- MACD
- NCL -0.03
- PHIO -0.04
- Stochastic Oscillator
- NCL 4.37
- PHIO 2.39
About NCL Northann Corp.
Northann Corp specialized in 3D-printed flooring solutions under its flagship brand, "Benchwick." The company's operations span the full spectrum of additive manufacturing, from sourcing recycled ocean plastics to the final production of intricate flooring designs. It offers an extensive range of proprietary solutions, including Infinite Glass, DSE, TruBevel, and MattMaster, mainly through its sales network in North America and Europe.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.